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 An accurate measurement of the immune status in patients with immune 
system disorders is critical in evaluating the stage of diseases and tailoring 
drug treatments. The functional cellular immunity test is a promising method 
to establish the diagnosis of immune dysfunctions. The conventional func-
tional cellular immunity test involves measurements of the capacity of 
peripheral blood mononuclear cells to produce pro-infl ammatory cytokines 
when stimulated ex vivo. However, this “bulk” assay measures the overall 
reactivity of a population of lymphocytes and monocytes, making it diffi -
cult to pinpoint the phenotype or real identity of the reactive immune cells 
involved. In this research, we develop a large surface micromachined poly-
dimethylsiloxane (PDMS) microfi ltration membrane (PMM) with high porosity, 
which is integrated in a microfl uidic microfi ltration platform. Using the PMM 
with functionalized microbeads conjugated with antibodies against specifi c 
cell surface proteins, we demonstrated rapid, effi cient and high-throughput 
on-chip isolation, enrichment, and stimulation of subpopulations of immune 
cells from blood specimens. Furthermore, the PMM-integrated microfi ltration 
platform, coupled with a no-wash homogeneous chemiluminescence assay 
(“AlphaLISA”), enables us to demonstrate rapid and sensitive on-chip immu-
nophenotyping assays for subpopulations of immune cells isolated directly 
from minute quantities of blood samples. 
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 The immune system plays a critical role in 
protecting a living organism against inva-
sions of viruses, bacteria, and parasitic 
worms, and distinguishes diseased tissue 
from healthy one. [ 1–4 ] Leukocytes (white 
blood cells) are important blood constitu-
ents that play a major role in innate and 
adaptive immune responses against path-
ogenic infections, allergic conditions, and 
malignancies. Leukocytes are a hetero-
geneous mixture of multiple cell subsets 
(granulocytes, lymphocytes, and mono-
cytes) defi ned by their morphology, sur-
face antigen expression, and production of 
cytokines – small proteins for intercellular 
communications between leukocytes of the 
same type (homotypic) or different types 
(heterotypic). [ 5–8 ] The numbers, propor-
tions and functional responses of leukocyte 
subsets change drastically in the presence 
of infections, malignancies, and autoim-
mune disorders, making analysis of leuko-
cyte subpopulations particularly valuable 965wileyonlinelibrary.com
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96in the diagnosis and monitoring of diseases. [ 4 , 9 ] For example, 
human immunodefi ciency virus (HIV) infection causes deple-
tion of CD4 + T cells in peripheral blood and other lymphoid tis-
sues. [ 1 , 10–12 ] As a result, the absolute counts of CD4 + T cells and 
the ratio of CD4 + / CD8 + T cells are commonly used as indica-
tors of the onset of the acquired immunodefi ciency syndrome 
(AIDS) and as benchmarks for the initiation of antiviral therapy 
to treat AIDS. 
 Leukocytes orchestrate immune responses by releasing 
cytokines. [ 2 , 9 , 13–17 ] Given the heterogeneity of leukocytes and 
different roles played by different subpopulations of leukocytes 
in the immune response, measurements of capacity to produce 
cytokines from different subpopulations of leukocytes become 
critically important in clinical diagnosis. Production of inter-
feron gamma (IFN- γ ) by T cells, for example, correlates with 
the body’s ability to mount a vigorous immune response and is 
used to identify antigen-specifi c T cells in diseases such as HIV 
and tuberculosis. [ 2 , 17 , 18 ] Sepsis is another serious clinical condi-
tion that results from dysregulation of the immune response to 
infection. [ 16 , 19–22 ] One hallmark of sepsis commonly reported is 
the decreased capacity of monocytes to release pro-infl amma-
tory cytokines such as tumor necrosis factor-alpha (TNF- α ) in 
response to ex vivo lipopolysaccharide (LPS) challenge. [ 16 ] 
 A signifi cant challenge in profi ling cytokine secretion in a 
heterogeneous cell suspension such as blood is the fact that the 
same cytokines can be produced by several different subpopula-
tions of leukocytes. For example, IFN- γ is commonly secreted 
by CD4 + T cells. However, IFN- γ can also be produced by CD8 + 
T ells, macrophages and neutrophils. In addition, the num-
bers and proportions of subpopulations of immune cells may 
vary in individuals and at different stages of diseases. Thus, 
measurements of the overall capacity of the whole population 6 wileyonlinelibrary.com © 2013 WILEY-VCH Verlag G
 Figure  1 .  Schematic of isolation and immunophenotyping of subpopulation
were recognized and captured by microbeads conjugated with monoclona
size of cell-microbead conjugates, the desired subpopulation of immune 
loading of the blood sample, while the other blood cells including undesir
immunophenotyping was then performed to examine the capacity of this s
lowing stimulation. of leukocytes to produce cytokines may not be informative 
enough to accurately reveal the immune status of patients, as 
in these ‘bulk’ assays it is diffi cult to pinpoint the phenotype 
or real identity of the reactive cells involved. As a result, the 
conventional whole blood stimulation assay routinely used in 
the clinical setting to determine cytokine secretion levels from 
the whole population of blood leukocytes is insuffi cient to accu-
rately defi ne and characterize the immune status of patients. 
 Here we reported a novel poly-dimethylsiloxane (PDMS) 
microfi ltration membrane (PMM) of a large surface area and 
high porosity for microfl uidic isolation and immunopheno-
typing of subpopulations of immune cells. The PMM was fab-
ricated using our newly developed surface micromachining 
technique for soft materials. [ 23 ] Recently, we have demosntrated 
that the PMM could serve as an effi cient microfi ltration mate-
rial for bioparticle separation during a sequence of processes 
entailing cell isolation, enrichment, enumeration, stimulation, 
incubation, and cytokine secretion detection on a single micro-
fl uidic chip for human peripheral blood mononuclear cells 
(PBMCs). [ 24 ] In this study, we further employed a combined use 
of the PMM and antibody-conjugated polystyrene microbeads 
for isolation, purifi cation, and functional immunophenotyping 
of different subpopulations of immune cells directly from blood 
specimens ( Figure  1 ). Immobilized on the microbead sur-
face were monoclonal antibodies against cell surface antigens 
specifi c to the desired subpopulation of immune cells. When 
mixed with a blood specimen, the microbeads could selectively 
capture the desired subpopulation of immune cells by recog-
nizing and binding covalently to the specifi c surface proteins 
of the cells. The diameter of the through holes in the PMM, 
which solely defi ned the effective size cutoff for microfi ltration, 
were designed to be smaller than the size of the microbeads mbH & Co. KGaA, Weinheim
s of immune cells from blood specimens. Subpopulations of immune cells 
l antibodies against specifi c cell surface antigens. Owing to the increased 
cells was retained on the PDMS microfi ltration membrane (PMM) upon 
ed immune cells could pass freely through the PMM. On-chip functional 
ubpopulation of immune cells to produce pro-infl ammatory cytokines fol-
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specimen was introduced into the microfi ltration device and 
forced to pass through the PMM, the cell/microbead conju-
gates were readily trapped and isolated on the PMM, whereas 
other untargeted leukocytes and erythrocytes (red blood cells) 
unbound to microbeads could freely pass through the PMM. 
Owing to its large surface area and high porosity, the PMM 
permitted a heightened volume throughput ( > 5 mL min  − 1 ) for 
processing blood specimens without causing clogging of the 
PMM, a common problem in microfi ltration membrane fi lters. 
 Our PMM-integrated microfi ltration device further allowed 
in situ quantitative immunosensing of cell-secreted cytokines 
by detecting optical signals resulted from a no-wash homoge-
neous sandwich chemiluminescence assay. In this homoge-
neous immunoassay, so called “AlphaLISA”, [ 25–27 ] the analyte 
of interest ( i.e. , cytokine) binds simultaneously to primary anti-
body-coated donor and acceptor beads, which brings the beads 
into a close proximity to each other. In this bead proximal state, 
singlet oxygen generated by laser excitation ( λ  = 680 nm) from 
the donor bead will transfer to the acceptor bead, eliciting a 
shorter wavelength emission ( λ  = 615 nm) from the acceptor 
bead. The AlphaLISA assay provides an effi cient way for quanti-
tative detection of cytokine production, without involving com-
plex reagent loading and washing steps as in the conventional 
fl uorescence-based immunoassays ( e.g. , enzyme-linked immu-
nosorbent assay (ELISA)). [ 28 , 29 ] 
 In addition, the miniaturized size of the PMM-integrated 
microfi ltration device required only a sample volume as small 
as 5  μ L for each assay. Our device, permitting the homogenous 
AlphaLISA immunoassay in a microfl uidic chamber, could 
reduce the entire assay time comprising the time for pretreat-
ment, process, and detection down to a few hrs, a nearly 10-fold 
reduction in total assay time as compared to the conventional 
whole blood stimulation assay using ELISA or the enzyme-
linked immunosorbent spot (ELISpot) assay. [ 28 , 29 ] Given the 
shortened assay time, enhanced sample effi ciency, and the 
ability to determine the functional status of different subpopu-
lations of immune cells, our microfl uidic immunophenotyping 
technology promises to provide a new approach to diagnosing 
infectious and infl ammatory diseases across a broad patient 
spectrum. 
 2. Results and Discussion 
 2.1. Microfi ltration Membrane Fabrication 
 PDMS is one of the most frequently used structural mate-
rials in microfl uidics. Yet, a major technical hurdle in micro-
fl uidics exists owing to the diffi culty in achieving high fi delity 
lithographic patterning on PDMS. Till now, surface patterning 
techniques of PDMS using conventional photolithography 
and etching processes have not been achieved. While soft 
lithography is a popular bulk micromachining technique for 
rapid fabrication of PDMS structures, thin microstructures 
such as microfi ltration membranes with micron-scale through 
holes are diffi cult to fabricate in PDMS by soft lithography. 
 Recently, we have reported a wafer-scale surface micro-
machining method for PDMS to generate different PDMS thin © 2013 WILEY-VCH Verlag GAdv. Healthcare Mater. 2013, 2, 965–975fi lm microstructures, with their critical dimensions ranging 
from sub-microns to tens of microns, using a combination 
of photolithography, reactive-ion etching (RIE), and conven-
ient thin fi lm releasing techniques. [ 23 ] Our method to achieve 
surface patterning of PDMS applies an O 2 plasma treatment 
to PDMS to activate its surface to overcome the challenge of 
poor photoresist adhesion on PDMS for photolithography. Uti-
lizing this newly developed PDMS surface micromachining 
technique, in this work we achieved wafer-scale batch fabri-
cation of large PDMS microfi ltration membranes (PMMs) 
containing a regular array of micron-scale through holes with 
high porosity (see Experimental Section and Figure S1 for the 
detailed fabrication procedure). Specifi cally, using our PDMS 
surface micromachining technique, we successfully fabricated 
PMMs with an effective membrane area of 3 cm  × 3 cm and 
porosity up to 30%; both factors could contribute to a height-
ened volume throughput for processing unprocessed blood 
specimens without causing clogging of the PMM, a common 
problem in microfi ltration membrane fi lters. For comparison, 
conventional track-etched polycarbonate fi lters, which have been 
used for isolation of blood cells and circulating tumor cells, has 
porosity of less than 2%, and the other more recently devel-
oped parylene-based micropore membrane has porosity of 7% - 
15%. [ 30–32 ] Since the through holes in the PMM were defi ned by 
photolithography, the size and pattern of the through holes in 
the PMM could be precisely controlled. The PMMs used in this 
work had a thickness of about 10  μ m and contained a regular 
array of hexagonally arranged through holes with a hole diam-
eter of 6 - 60  μ m and a center-to-center distance of 10 – 100 
 μ m ( Figure  2 A-C). By controlling anisotropic etching of PDMS 
using RIE, the through holes of the PMM had a near vertical 
sidewall profi le (Figure  2 C). The transparent nature of PDMS 
permitted imaging and enumeration of cells captured on the 
PMM using standard clinical histopathological stains, in addi-
tion to immunofl uorescence-conjugated antibodies. 
 Our PDMS surface micromachining technique is compatible 
with soft lithography techniques and other silicon-based micro-
fabrication methods. Thus, the PMM can be easily integrated 
with PDMS supporting structures and other PDMS-based 
molecular and cellular analysis components while maintaining 
a large surface area and high porosity (Figure  2 D). In this study, 
using O 2 plasma-assisted PDMS-PDMS bonding, the PMM was 
assembled with two structured PDMS layers serving as the top 
cell culture chamber and the bottom immunoassay chamber to 
form a completely sealed PMM-integrated microfi ltration device. 
The cell culture chamber and the immunoassay chamber in the 
microfi ltration devices contained supporting pillar structures to 
provide the aforementioned mechanical strength for the PMM 
during cell fi ltration process (Figure  2 E). 
 2.2. Capture of Subpopulation of Immune Cells Using 
Microbeads Conjugated with Antibodies 
 Surface functionalized micro/nano scale beads and particles 
are widely used for isolations of cells and proteins. Leukocytes 
are known to produce specifi c antigens on their surfaces. By 
using the biotin-streptavidin conjugation chemistry to coat 
polystyrene microbeads with antibodies directed against specifi c 967wileyonlinelibrary.commbH & Co. KGaA, Weinheim
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 Figure  2 .  SEM images showing free-standing PMMs with high porosity. (A-C) Top (A&B) and tilted 
(C) view SEM images showing PMMs containing a regular array of hexagonally arranged through 
holes with the hole diameter of either 6  μ m (A), 30  μ m (B), or 60  μ m (C). The PMMs had a thickness 
of 10  μ m. (D) Top view SEM image showing PDMS supporting pillars with a height of 100  μ m and 
a diameter of 60  μ m. (E) SEM image showing a cross-section view of a free-standing PMM bound 
to PDMS supporting posts. In E, the diameter of the PMM through hole was 30  μ m. cell surface antigens, these microbeads could recognize and 
capture desired subpopulations of immune cells expressing 
specifi c surface proteins. Owing to the signifi cant physical size 68
 Figure  3 .  Capture of immune cells using microbeads conjugated with anti-CD14 antibodies. 
(A-C) Representative merged brightfi eld and fl uorescence images showing THP-1 cells (green; 
A&B) and CD14 + monocytes (green; C) captured by microbeads in either culture media (A) 
or lysed blood (B&C). The microbeads with a diameter of 32  μ m were conjugated with anti-
CD14 monoclonal antibodies. THP-1 cells were pre-stained with CellTracker Green. Blood leuko-
cytes in B&C were pre-stained with DiI (B) or CellTracker Green (C). (D-F) Distributions of the 
number of cells captured per bead for THP-1 cells (D&E) and CD14 + monocytes (F) in either 
culture media (D) or lysed blood (E&F). For D&E, 2  × 10 6 THP-1 cells were mixed with 4  × 10 5 
microbeads in 1 mL cell culture media (D) or lysed blood (E). For F, 2 mL lysed blood containing 
about 2  × 10 7 leukocytes was mixed with 3  × 10 5 microbeads. Gaussian functions (red curves) 
were used for fi tting in D-F. (G) Capture rate of functionalized microbeads for THP-1 cells 
spiked in growth media, in growth media with PBMCs, and in lysed blood as indicated. Error 
bars represent  ± standard error of the mean (s.e.m;  n  = 4). difference between the microbeads and leu-
kocytes, when the blood sample was passing 
through the PMM, the desired subpopula-
tion of immune cells that were bound to 
functionalized microbeads could be effi -
ciently isolated by the PMM, while the other 
blood cells including undesired immune 
cells would pass freely through the PMM. 
 We fi rst characterized the capture effi -
ciency of functionalized microbeads with 
a diameter of 32  μ m and conjugated with 
monoclonal antibodies directed against 
CD14, a unique surface protein marker of 
monocytes. Well-controlled quantities of the 
microbeads were mixed with known quan-
tities of fl uorescence-tagged CD14 + THP-1 
cells, a human acute monocytic leukemia 
cell line as a model for human monocytes. 
THP-1 cells were suspended in either blank 
culture media, culture media spiked with 
known quantities of peripheral blood mono-
nuclear cells (PBMCs) mimicking blood leu-
kocytes, or lysed blood that was pre-stained 
with DiI to label blood leukocytes (see Exper-
imental Section for details; the concentra-
tions of THP-1 cells and microbeads were 
2  × 10 6 mL  − 1 and 4  × 10 5 mL  − 1 , respectively). 
We also mixed well-controlled quantities of 
the microbeads directly with lysed blood that 
was pre-stained with Calcein AM to label wileyonlinelibrary.com © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinblood leukocytes at a concentration of 10  × 
10 6 mL  − 1 . The mixture of the microbeads and 
immune cells were incubated for 2 hrs on 
a roller mixer before they were examined 
under fl orescence microscopy ( Figure  3 A-
C). Our results in Figure  3 D&E showed that 
for THP-1 cells spiked in growth media or 
lysed blood, on average, there were about 4 
THP-1 cells bound to a single microbead 
following cell-bead mixing and incubation. 
Similar to results for THP-1 cells, on average, 
there were about 4 CD14 + monocytes from 
lysed blood bound to a single microbead 
following cell-bead mixing and incuba-
tion (Figure  3 F). We further quantifi ed the 
overall capture effi ciency of the microbeads 
for THP-1 cells (defi ned as the ratio between 
the total number of THP-1 cells captured by 
microbeads and the total number of THP-1 
cells in the sample). Our results in Figure  3 G 
showed that for THP-1 cells spiked in culture 
media or lysed blood, the capture effi ciency 
of the microbeads conjugated with anti-CD14 
antibodies was all greater than 70%. Together, 
our data in Figure  3 strongly supported the 
utility of functionalized microbeads for effi -cient recognition and capture of desired subpopulations of 
immune cells from a complex mixture of background cells, 
such as blood leukocytes. heim Adv. Healthcare Mater. 2013, 2, 965–975
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 Figure  4 .  Characterization of capture effi ciency of the PMM using fl orescence-tagged 
microbeads. (A) Temporal sequence of merged brightfi eld and fl uorescence images showing 
isolation of 6  μ m (top), 15  μ m (middle), and a mixture of 6  μ m and 15  μ m (1:1 ratio; bottom) 
fl orescence-tagged microbeads on a PMM with the through hole diameter of 13  μ m. The 
microbead concentration was 2  × 10 4 mL  − 1 , and they were injected through the PMM with a 
volume fl ow rate of 100  μ L min  − 1 . Virtually all 15  μ m beads were trapped on the PMM while 
all 6  μ m beads passed through the PMM. (B&C) Captured yield of 6  μ m (B) and 15  μ m (C) 
microbeads as a function of the total number of microbeads injected through the PMM. Data 
was calutlated from the top and middle panels of images shown in A. (D) Captured yield of 
6  μ m and 15  μ m microbeads from a mixture of 6  μ m and 15  μ m microbeads, as a function 
of the total number of microbeads injected through the PMM. Data was calculated from the 
bottom panel of images shown in A. (E) Capture yield of 15  μ m microbeads as a function of 
the volume fl ow rate. The microbead concentration was 2  × 10 4 mL  − 1 , and they were injected 
through the PMM with a varied volume fl ow rate. Error bars in B-E represent  ± s.e.m. ( n  = 4).  2.3. Characterization of Capture Effi ciency of the PMM 
for Microbeads and Cells 
 We fi rst characterized the capture effi ciency of the PMM using 
well-controlled quantities of fl uorescence-tagged polystyrene 
microbeads spiked in PBS ( Figure  4 ). The PMM used in these 
assays contained a regular array of through holes with a hole 
diameter of 13  μ m and a center-to-center distance of 20  μ m. The 
porosity of the PMM was about 25%. Two different sized poly-
styrene microbeads were assayed with the means of their dia-
meters of 6  μ m and 15  μ m. The microbeads at a concentration of 
2  × 10 4 mL  − 1 in the PBS were injected into the PMM-integrated 
microfi ltration device using a syringe infusion pump under a 
constant fl ow rate of 100  μ L min  − 1 . The fl uorescence-tagged 
microbeads trapped on the PMM could be visually examined 
and enumerated under bright-fi eld and fl uorescence micro scopy 
(Figure  4 A). Since the diameter of the through holes in the 
PMM was 13  μ m, smaller than the 15  μ m microbeads but larger © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, WeinhAdv. Healthcare Mater. 2013, 2, 965–975than the 6  μ m ones, the PMM would capture 
virtually all the 15  μ m microbeads while let-
ting all the 6  μ m ones passing through. Our 
quantitative results in Figure  4 B-D demon-
strated an extremely high effi ciency of the 
PMM to separate the two different sized 
microbeads, as evidenced by a capture yield 
(defi ned as the ratio of the number of beads 
captured on the PMM to the total number of 
beads injected) and purity of 97.2% and 98%, 
respectively, for the 15  μ m microbeads. 
 As shown in Figure S2, by integrating dif-
ferent layers of PMMs with supporting pillars 
in a single microfl uidic device, we developed 
a three-dimensional (3-D) multilayer gradient 
microfi ltration device that could achieve effi -
cient isolation and enrichment of different 
sized bioparticles simultaneously. The sizes 
of and the distances between the through 
holes on each PMM in the 3-D multilayer 
microfi ltration device gradually decreased 
along the separation path, enabling a gradient 
fi ltration scheme. As shown in Figure S2, 
we could isolate and enrich both 15  μ m and 
6  μ m microbeads simultaneously in an inte-
grated double-layer microfi ltration device, in 
which the diameter of the through holes in 
the top and bottom PMMs were chosen to be 
13  μ m and 5  μ m, respectively. The 3-D multi-
layer gradient microfi ltration device, when 
combined with different-sized antibody-
conjugated microbeads targeting different 
surface proteins, could, in principle, provide 
an effective solution for isolation and enrich-
ment of multiple subpopulations of immune 
cells simultaneously from blood specimens. 
 We further examined the effect of fl ow 
rate on the capture effi ciency of the PMM, 
by comparing the capture effi ciency of the 
PMM for 32  μ m microbeads under dif-
ferent fl ow rate conditions (from 1 - 20 mL min  − 1 ; Figure  4 E). The PMM contained an array of hexagonally 
arranged through holes of 30  μ m in diameter and with a center-
to-center distance of 50  μ m. Our results in Figure  4 E suggested 
that the PMM was able to achieve extremely high capture effi -
ciency for the microbeads even under a fl ow rate as high as 
20 mL min  − 1 , without evidence showing plastic deformation 
or fracture of the PMM under the microscopy, which might be 
attributable to the PDMS supporting pillars integrated in the 
microfi ltration device. 
 We next characterized the performance of the PMM with the 
through hole diameter of 30  μ m for isolation of THP-1 cells 
bound to 32  μ m microbeads functionalized with anti-CD14 
antibodies ( Figure  5 ). Here known quantities of THP-1 cells 
(2  × 10 6 ) labeled with CellTracker Green were mixed and incu-
bated with the functionalized microbeads (4  × 10 5 ) for 2 hrs 
in either 1 mL cell culture medium containing 5  × 10 6 mL  − 1 
PBMCs or 1 mL lysed blood containing about 6  × 10 6 mL  − 1 leu-
kocytes and 5  × 10 5 mL  − 1 CD14 + monocytes. Different volumes 969wileyonlinelibrary.comeim
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 Figure  5 .  Characterization of capture effi ciency of the PMM using samples spiked with THP-1 cells. (A&B) Representative brightfi eld, fl uorescence, and 
merged microscopic images showing fl uorescence-tagged THP-1 cells bound to microbeads isolated on the PMM. THP-1 cells labeled with CellTracker 
Green were spiked in either cell culture media (A) or lysed blood pre-stained with DiI to label blood leukocytes (B). The microbeads with a diameter 
of 32  μ m were conjugated with anti-CD14 antibodies. The PMM had a through hole diameter of 30  μ m. (C) Regression analysis of capture effi ciency 
of the PMM for the functionalized microbeads used for capturing THP-1 cells. The plot represents the number of microbeads (bound with or without 
cells) captured on the PMM against the total number of microbeads (bound with or without cells) injected through the PMM. (D) Capture yield of 
microbeads (bound with or without cells) as a function of the total number of microbeads (bound with or without cells) injected through the PMM. 
(E&F) Capture yield (E) and purity (F) of THP-1 cells on the PMM. For C-F, known quantities of THP-1 cells (2  × 10 6 ) were mixed with microbeads 
(4  × 10 5 ) in 1 mL cell culture media (red symbols or bars), 1 mL cell culture media containing 5  × 10 6 mL  − 1 PBMCs (green symbols or bars), or 1 mL 
lysed blood containing about 6  × 10 6 mL  − 1 leukocytes (blue symbols or bars), as indicated. The volume fl ow rate was 1 mL min  − 1 . Solid lines in C&D 
represent linear fi tting. Error bars represent  ± s.e.m ( n  = 4). of the culture medium and lysed blood samples were injected 
into the PMM-integrated microfi ltration device at a fl ow rate of 
1 mL min  − 1 . The cells bound to the microbeads trapped on the 
PMM were examined under fl uorescence microscopy to deter-
mine the capture effi ciencies for the microbeads and THP-1 cells 
(Figure  5 A&B). As expected, virtually all the 32  μ m microbeads 
( > 99%), regardless whether bound with or without cells, were 
captured on the PMM (Figure  5 C&D). The capture yield of 
THP-1 cells, defi ned here as the ratio between the number of 
THP-1 cells bound to microbeads captured on the PMM to the 
total number of THP-1 cells injected into the microfi ltration 
device, was all greater than 70%, regardless whether THP-1 
cells were spiked in culture media, culture media containing 
PBMCs, or lysed blood. In addition, capture purities of THP-1 
cells, defi ned as the ratio between the number of THP-1 cells 
bound to microbeads captured on the PMM to the total number 
of cells captured on the PMM, was on average as high as 97%, 
regardless whether THP-1 cells were spiked in culture media, 
culture media containing PBMCs, or lysed blood. Together, our 
data in Figure  5 convincingly supported our approach of using 
functionalized microbeads and the PMM for effi cient capture 
and isolation of subpopulations of immune cells with a high 
purity. From our data in Figure  5 , we also concluded that the 
overall capture yield of our method to isolate subpopulations 
of immune cells was largely determined by the yield of the cell 
capture process using the functionalized microbeads, not by 
the microbead isolation process using the PMM. 70 wileyonlinelibrary.com © 2013 WILEY-VCH Verlag G 2.4. Isolation of Subpopulation of Immune Cells 
from Human Blood 
 Using the PMM coupled with functionalized microbeads, we 
demonstrated direct isolation, enrichment, and enumeration 
of CD14 + monocytes from both lysed as well as whole blood 
specimens ( Figure  6 A-C). As a control, we fi rst used a PMM 
with the through hole diameter of 6  μ m to isolate the whole 
population of leukocytes from lysed blood (Figure  6 A). Leuko-
cytes in the lysed blood were stained with Calcein AM for visu-
alization. Lysed blood with the leukocyte concentration of 5  × 
10 6 mL  − 1 or diluted lysed blood with the leukocyte concentra-
tion of 1  × 10 6 mL  − 1 was fi ltered by the PMM with the through 
hole diameter of 6  μ m in the microfi ltration device at a fl ow 
rate of 1 mL min  − 1 . The number of leukocytes trapped on the 
PMM increased lineally with the sample injection volume, and 
our regression analysis of capture effi ciency of the PMM for 
leukocytes in Figure  6 D revealed that about 93% of leukocytes 
in the lysed blood were captured on the PMM under a fl ow rate 
of 1 mL min  − 1 . 
 To isolate CD14 + monocytes from human blood, known 
quantities of functionalized 32  μ m microbeads conjugated 
with anti-CD14 antibodies were added into blood samples. 
Prior to this, leukocytes in the blood sample were pre-labeled 
with Calcein AM. After 2-hr mixing and incubation, the blood 
specimens were injected through a PMM with the through hole 
diameter of 30  μ m. Our results in Figure  6 E showed that about mbH & Co. KGaA, Weinheim Adv. Healthcare Mater. 2013, 2, 965–975
www.MaterialsViews.com
FU
LL P
A
P
ER
www.advhealthmat.de
 Figure  6 .  Isolation of CD14 + monocytes from blood specimens using the PMM. (A-C) Repre-
sentative merged brightfi eld and fl uorescence images showing fl urescence-tagged leukocytes 
(A) and CD14 + monocytes (B&C) from lysed blood (A&B) or whole blood (C) isolated on the 
PMM. The PMM had a through hole diameter of 6  μ m (A) or 30  μ m (B&C). CD14 + monocytes 
were fi rst captured by 30  μ m microbeads conjugated with anti-CD14 antibodies before the 
cell-microbead conjugates were isolated on the PMM. Leukocytes in the blood samples were 
stained with Calcein AM for visualization. (D) Regression analysis of capture effi ciency of the 
PMM with the through hole diameter of 6  μ m for blood leukocytes, under a fl ow rate of 1 mL 
min  − 1 . The plot represents the number of leukocytes captured on the PMM against the number 
of leukocytes injected through the PMM, using undiluted (5  × 10 6 mL  − 1 ) as well as diluted 
(1  × 10 6 mL  − 1 ) lysed blood samples as indicated. Solid lines represent linear fi tting. (E&F) 
Percentage (E) and purity (F) of CD14 + monocytes captured using functionalized microbeads 
and the PMM from lysed and whole blood. For E&F, known quantities of microbeads (3  × 10 5 ) 
were mixed with 2 mL lysed and whole blood (containing about 2  × 10 7 leucocytes). The shaded 
area in E indicates the normal percentage range of CD14 + monocytes in blood from healthy 
adults. Error bars represent  ± s.e.m. ( n  = 4). 6.0% and 3.5% leukocytes from the lysed and whole blood 
samples, respectively, were bound to the 32  μ m microbeads 
and subsequently captured by the PMM with the through hole 
diameter of 30  μ m as CD14 + monocytes. These results are con-
sistent with the fact that the normal percentage range of CD14 + 
monocytes in blood from healthy adults is from 2% - 8%. [ 33 , 34 ] 
Compared to the results for lysed blood, the capture yield of 
CD14 + monocytes from whole blood was slightly lower, likely 
due to the large number of erythrocytes (red blood cells) and 
other undesired leukocytes in whole blood blocking effective 
interactions between CD14 + monocytes and functionalized 
microbeads. 
 2.5. Functional Immunophenotyping of Subpopulations 
of Immune Cells 
 We further demonstrated functional immunophenotyping of 
subpopulations of immune cells using the PMM-integrated © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, WeinAdv. Healthcare Mater. 2013, 2, 965–975microfi ltration device combined with a 
rapid, no-wash, quantitative immunosensing 
method, the AlphaLISA, [ 25–27 ] using minute 
quantities of blood. The overall immunophe-
notyping assay protocol using the micro-
fi ltration device was shown in  Figure  7 A 
(see Experimental Section for details). After 
the desired subpopulation of immune cells 
( e.g. , CD14 + monocytes) was captured and 
enriched by functionalized microbeads and 
the PMM from blood specimens (Step 1 in 
Figure  7 A), the cells trapped on the PMM 
were stimulated and incubated with LPS 
loaded from the inlet of the top cell culture 
chamber of the microfi ltration device (Step 2 
in Figure  7 A). LPS is a canonical endotoxin 
that can cause septic shock in the human 
body due to severely pronounced immune 
response. Pro-infl ammatory cytokines 
secreted from LPS-stimulated immune cells 
would diffuse rapidly through the PMM to 
the bottom immunoassay chamber, where 
the AlphaLISA donor and acceptor beads 
were loaded and optically detected  in situ for 
quantitative immunosening (Step 3 in Figure 
 7 A). The AlphaLISA signal detected could be 
converted to the cytokine concentration using 
standard curves generated using AlphaLISA 
with samples spiked with known concentra-
tions of cytokines (Figure S3). 
 In this research, we applied the PMM-
integrated microfi ltration device and the 
AlphaLISA to detect secretion of TNF- α 
from LPS-stimulated CD14 + monocytes iso-
lated from blood specimens. TNF- α is a pro-
infl ammatory cytokine and a key biomarker 
associated with host defense and immu-
nosurveillance. Secretion of TNF- α from 
LPS-stimulated monocytes has been shown 
to refl ect the functional status of the innate immune response. Our data in Figure  7 B showed that TNF- α 
secretion from LPS-stimulated free THP-1 cells and THP-1 cells 
bound to microbeads were very similar, leading us to conclude 
that binding to anti-CD14 antibodies on microbeads would not 
signifi cantly affect TNF- α secretion from CD14 + monocytes. 
 We next applied the PMM-integrated microfi ltration device 
and the AlphaLISA for quantitative immunosensing of 
cytokines secreted from LPS-stimulated CD14 + monocytes 
isolated directly from lysed blood. The results were compared 
with cytokine secretions from LPS-stimulated leukocytes iso-
lated directly from lysed blood and from LPS-stimulated THP-1 
cells. In these assays, equal numbers of THP-1 cells, leuko-
cytes and CD14 + monocytes (about 2  × 10 4 ) were trapped on 
the PMM before quantitative immunosensing. Our result in 
Figure  7 C demonstrated that similar to THP-1 cells, TNF- α 
secreted by CD14 + monocytes isolated directly from lysed blood 
would increase with LPS concentration. Further, the amount of 
TNF- α secreted by CD14 + monocytes was very comparable to 
that from THP-1 cells but signifi cantly higher as compared to 971wileyonlinelibrary.comheim
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 Figure  7 .  Immunophenotyping of subpopulations of immune cells isolated from human blood. (A) Schematic showing the immunophenotyping assay 
protocol using the PMM-integrated microfi ltration device and the AlphaLISA: (1) isolation and enrichment of CD14 + monocytes on the PMM from 
blood samples; (2) LPS stimulation of CD14 + monocytes trapped on the PMM to release pro-infl ammatory cytokines; (3) Loading and incubation 
of AlphaLISA beads in the immunoassay chamber; (4) Detection of TNF- α using the AlphaLISA, in which the streptavidin-coated donor (blue) and 
acceptor beads (orange) were both conjugated with TNF- α antibodies. The beads were brought into a close proximity ( < 200 nm) through binding 
simultaneously to TNF- α . Using a 680 nm laser for excitation, the singlet oxygen released by the donor bead would diffuse to the nearby acceptor 
bead and trigger it to emit the 615 nm fl uorescent light. Measurement of this emission light from the acceptor beads using our custom optical setup 
(Figure S3) would allow a quantitative detection of TNF- α secretion. (B) Comparison of TNF- α secretions from LPS-stimulated free THP-1 cells and 
THP-1 cells bound to microbeads. (C&D) Comparative study of TNF- α secretion from LPS-stimulated THP-1 cells, leukocytes isolated directly from 
lysed blood, and CD14 + monocytes isolated from lysed blood. For C&D, about 2  × 10 4 THP-1 cells, leukocytes, and CD14 + monocytes were trapped 
on the PMM before quantitative immunosensing. C&D plot the bulk TNF- α concentration and TNF- α molecules secreted per cell, respectively, as a 
function of LPS concentration. Solid lines in D represent linear fi tting. Error bars represent  ± s.e.m. ( n  = 4).  P -values were calculated using the paired 
student’s  t -test.  ns ( P  > 0.05; not signifi cant),  ∗ ( P  < 0.05). TNF- α secretions from leukocytes isolated directly from lysed 
blood, confi rming the functional heterogeneity between dif-
ferent types of immune cells. 
 3. Conclusions 
 In summary, here we developed a unique surface-microma-
chined bioparticle separation membrane made of elastometric 
organosilicon compounds, named the “PDMS microfi ltration 
membrane (PMM)”. Integrating the PMM in a microfl uidic 
microfi ltration device, we successfully demonstrated a simple wileyonlinelibrary.com © 2013 WILEY-VCH Verlag Gyet effi cient strategy for on-chip isolation and enrichment 
of subpopulations of immnue cells bound to functionalized 
microbeads conjugated with antibodies against specifi c cell sur-
face proteins. Owing to the high porosity and large surface area 
of the PMM, our PMM-integrated microfi ltration device could 
process lysed and whole blood samples with a high volume 
throughput (up to 20 mL min  − 1 ). Our microfi ltration device 
could achieve high capture yield (about 70%, largely depending 
on the cell-microbead capture process) and excellent capture 
purity ( > 97%) for subpopulations of immune cells from blood 
samples. Further, our microfi ltration device could be directly 
integrated with the AlphaLISA biosensing technique and used mbH & Co. KGaA, Weinheim Adv. Healthcare Mater. 2013, 2, 965–975
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subpopulations of immune cells isolated directly from minute 
quantities of blood samples. All together, our PMM-integrated 
microfl uidic functional immunophenotyping technology could 
perform rapid, accurate, and sensitive cellular functional assays 
on different types or subpopulations of immune cells, which 
could provide an unprecedented level of information depth on 
the distribution of immune cell functionalities. Such an inno-
vative tool enabled by the cell separation performance of the 
PMM will potentially allow comprehensive and systems-level 
immunomonitoring to defi ne and characterize the “immuno-
type” of healthy individuals and patients, critical for clinical 
interventions and managements of patients with immune 
system disorders. 
 4. Experimental Section 
 Surface Micromachining of PMM: The PMM was fabricated using the 
surface micromachining technique for soft materials we have developed 
previously (Figure S1). Briefl y, a silicon wafer was fi rst activated using 
the O 2 plasma (Plasma Cleaner PDC-001, Harrick Plasma, Ithaca, NY) 
for 2 min and silanized with (tridecafl uoro-1,1,2,2,-tetrahydrooctyl)-1-
trichlorosilane vapor (United Chemical Technologies, Bristol, PA) for 
1 hr under vacuum to facilitate subsequent release of patterned PDMS 
layers. PDMS prepolymer (Sylgard-184, Dow Corning, Midland, MI) was 
prepared by thoroughly mixing the PDMS curing agent with the PDMS 
base monomer ( wt :  wt  = 1: 10). PDMS prepolymer was then spin-
coated on the silanized silicon wafer at a spin speed of 7,000 rpm and 
completely cured after baking at 110  ° C for 4 hrs. The PDMS surface was 
activated using the O 2 plasma for 5 min to allow a uniform photoresist 
coating for photolithography. After the O 2 plasma activation, photoresist 
(AZ 9260, AZ Electronic Materials, Branchburg, NJ) was spin-coated on 
PDMS, soft-baked at 90  ° C for 10 min, and then patterned using contact 
photolithography. The silicon wafer was then processed with reactive 
ion etching (RIE; LAM 9400, Lam Research, Fremont, CA) using SF 6 
and O 2 gas mixtures to transfer patterns from patterned photoresist 
to the underlying PDMS layer. During RIE, reactive gas ions would etch 
exposed PDMS regions anisotropically. Photoresist was then striped 
using organic solvents, leaving patterned PDMS thin fi lms on the silicon 
wafer. 
 Microfl uidic Device Fabrication and Assembly: The structure of the 
PMM-integrated microfl uidic immunosensing device consisted of three 
different PDMS layers. The top and bottom PDMS layers were the 
cell culture and immunoassay chambers, respectively, and the middle 
layer was the PMM. The cell culture and immunoassay chambers were 
fabricated using soft lithography. Briefl y, silicon molds were fi rst fabricated 
using photolithography and deep reactive ion-etching (DRIE) (Deep 
Silicon Etcher, Surface Technology Systems, Allentown, PA). The silicon 
molds were then silanized with (tridecafl uoro-1,1,2,2,-tetrahydrooctyl)-
1-trichlorosilane vapor (United Chemical Technologies) for 4 hrs under 
vacuum to facilitate subsequent release of PDMS sturcutures from the 
silicon molds. PDMS prepolymer with a 1:10  wt ratio of PDMS curing 
agent to base monomer was poured onto the silicon molds and cured 
at 110  ° C for 4 hrs. Fully cured PDMS structures were peeled off from 
the silicon molds, and excessive PDMS was trimmed using a razor 
blade. The O 2 plasma-assisted PDMS-PDMS bonding process was then 
used to assemble the cell culture and immunoassay chambers with the 
PMM to form a completely sealed microfl uidic immunosensing device. 
Assembly of the microfl uidic immunosensing device was performed 
under eye inspection using some alignment marks on the cell culture 
and immunoassay chamber layers. 
 Scanning Electron Microscopy (SEM) Imaging: SEM images were taken 
to inspect the geometrical features of the PMM and the microfl uidic 
immunosensing device. Briefl y, the sample under inspection was 
mounted on stubs, sputtered with gold palladium, observed and © 2013 WILEY-VCH Verlag GAdv. Healthcare Mater. 2013, 2, 965–975photographed under a Hitachi SU8000 Ultra-High Resolution SEM 
machine (Hitachi High Technologies America, Inc., Pleasanton, CA). 
 Cell Culture and Reagents: THP-1 cells (ATCC, Manassas, VA) were 
cultured in the cell growth medium (RPMI-1640, ATCC, Manassas, VA) 
supplemented with 0.05 mM 2-mercaptoethanol (Invitrogen, Carlsbad, 
CA) and 10% ( v / v ) heat-inactivated fetal bovine serum (FBS; Atlanta 
Biological, Atlanta, GA). Cells were maintained at 37 ° C with 5% CO 2 
and 100% humidity and passaged every two days. 
 Human Blood Specimen Collection and Processing: Human blood 
specimens were obtained from healthy donors and collected into the 
vacutainer containing ethylenediaminetetraacetic acid (EDTA) according 
to the standard protocol. Human blood specimens were processed and 
assayed within 6 hrs after blood collection. To lyse blood, RBC Lysis 
Buffer (eBioscience, San Diego, CA) was added to whole blood at a 10:1 
 v/v ratio. After incubation for 10 min at room temperature, the Lysis 
Buffer was diluted with 20 −30 mL PBS to stop lysing reaction. Then 
the solution was centrifuged at 300 g for 10 min before the supernatant 
was removed. Immune cells in the cell pellet were re-suspended in 
the cell growth medium before they were used for cell capture assays 
with functionalized microbeads. For whole blood assays, human blood 
specimen was centrifuged at 300 g for 10 min to remove plasma and 
supernatant before the specimen was used for cell capture assays with 
functionalized microbeads. 
 Cell Capture Using Microbeads Conjugated with Antibodies: For 
visualization, THP-1 cells were labeled with CellTracker Green (1  μ M; 
Invitrogen) before spiked into cell culture media, while leukocytes in 
blood specimens were labeled with  Δ 9 -DiI (2  μ M; Invitrogen). Then 
known quantities (4  × 10 5 ) of polystyrene microbeads conjugated with 
anti-CD14 monoclonal antibodies (pluriSelect GmbH, Leipzig, Gemany) 
were mixed with known quantities of THP-1 cells (2  × 10 6 ) in 1 mL cell 
culture media, or cell culture media containing PBMCs (5  × 10 6 ) or lysed 
blood (6  × 10 6 leukocytes). After the sample and beads were mixed and 
incubated at room temperature for 1−2 hrs on a roller mixer (Invitrogen), 
target cells bound to the microbeads and ready for further isolation. 
For cell capture using real lysed blood or whole blood, known quantity 
of microbeads (3  × 10 5 ) were mixed with the prepared lysed blood 
sample containing 20  × 10 6 leukocytes in 2 mL cell culture medium and 
incubated at room temperature for 1-2 hrs on a roller mixer (Invitrogen). 
Then the leukocytes in samples were labeled with Calcein AM (working 
concentration 10  μ M; Invitrogen) for visualization. 
 Capture of Microbeads and Cells Using PMM : To prevent non-specifi c 
interactions between the PMM and microbeads or immune cells, the 
microfl uidic device containing the PMM was fi rst fi lled with 2% ( w / w ) 
Pluronics F127 (P2443-250G, Sigma) in PBS for 10 min. The microfl uidic 
device was then fl ushed twice with PBS to remove residual Pluronics 
F127 molecules. For microbead and cell capture assays, known 
quantities of microbeads or microbeads bound with immune cells were 
loaded into the microfi ltration device using a syringe infusion pump 
(World Precision Instruments, Sarasota, FL) at a fl ow rate between 
0.2 − 20 mL min  − 1 . Captures of microbeads and immune cells on the 
PMM were monitored real-time under an inverted microscope (Nikon 
Eclipse Ti-S, Nikon, Melville, NY) equipped with an electron multiplying 
charge-coupled device (EMCCD) camera (Photometrics, Tucson, AZ). 
Sequential brightfi eld and fl uorescence images were taken using a 10 × 
objective (Ph1 ADL, numerical aperture or N.A.  = 0.25, Nikon). A 130 W 
mercury lamp (Intensilight C-HGFIE, Nikon) was used in the microscope 
for illumination. 
 Quantifi cation of Capture Effi ciency of the PMM: The concentrations 
of microbeads as well as cells in each sample were fi rst determined 
using a hemocytometer. The microbeads and cells isolated on the PMM 
were then imaged using fl uorescence microscopy (Nikon Eclipse Ti-S, 
Nikon). To quantify capture effi ciency of the PMM, the whole surface 
area of the PMM was scanned using a motorized stage (ProScan 
III, Prior Scientifi c, Rockland, MA). The images were stitched using 
microscopic analysis software, the NIS-Element BR from Nikon. Image 
processing software ImageJ (National Institutes of Health, Bethesda, 
MD) was then used to determine the total number of beads and cells 
captured on the PMM. 973wileyonlinelibrary.commbH & Co. KGaA, Weinheim
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974 Immunophenotyping Assay using AlphaLISA: The overall 
immunophenotyping assay protocol is shown in Figure  6 A. First, known 
quantities of immune cells (free-fl oating or bound to microbeads) in 
cell culture media, lysed blood or whole blood were loaded into the 
microfi ltration device by a syringe pump (World Precision Instruments). 
After the cells were uniformly seeded on the PMM, 10  μ L solutions 
of LPS (L5886, Sigma) of different concentrations (10, 50, and 
100 ng mL  − 1 ) were loaded into the microfi ltration device from the inlet 
of the cell culture chamber using pipette tips. After LPS loading, two 
pipette tips were inserted into the inlets of both the cell culture and 
immunoassay chambers to prevent evaporation and provide a shear 
stress free microenvironment for cell stimulation. The microfi ltration 
device was then incubated at 37 ° C with 5% CO 2 for 2 hrs. Then, the 
pipette tip inserted into the inlet of the immunoassay chamber was 
replaced by another pipette tip fi lled with 10  μ L AlphaLISA acceptor 
beads (10  μ g mL  − 1 ; PerkinElmer, Waltham, MA) mixed with 10  μ L 
biotinylated TNF- α antibody (10 nM). AlphaLISA acceptor beads injected 
into the microfi ltration device were incubated with the immune cells at 
37 ° C with 5% CO 2 for 1 hr, before another pipette tip fi lled with 10  μ L 
AlphaLISA streptavidin-coated donor beads (400  μ g mL  − 1 ) was loaded 
into the inlet of the immunoassay chamber. The whole microfi ltration 
device was incubated at 37  ° C with 5% CO 2 for another 30 min. During 
the whole 1.5-hr AlphaLISA bead incubation period, TNF- α secreted by 
LPS-stimulated immune cells would diffuse from the top cell culture 
chamber through the PMM into the bottom immunoassay chamber 
to conjugate with antibody-coated donor and acceptor beads. After 
AlphaLISA bead incubation, the mirofi ltration device was placed into our 
custom optical setup for AlphaLISA signal detection. 
 Optical Setup for Detection of AlphaLISA Signal: The microfi ltration 
device was placed on a custom optical setup for detection of the 
AlphaLISA signal (Figure S3). In this setup, a 500 mW 680 nm 
laser diode (S-67-500C-100-H, Coherent, Clara, CA) was used as an 
excitation light to induce singlet oxygen from AlphaLISA donor beads. 
An electronic shutter (SmartShutter, Lambda SC, Shutter Instrument, 
Novato, CA) was placed in front of the laser to control the timing of 
laser pulse for excitation. The laser light was guided into the inverted 
fl uorescent microscope (Nikon Eclipse Ti-S, Nikon) and passed through 
the excitation fi lter (680/13nm BrightLine, Semrock, Rochester, New 
York) and dichroic mirror (ZT660dcspxr, Chroma, Bellows Falls, VT). 
The 2X objective (CFI Plan Achromat, N.A.  = 0.06, Nikon) was used 
to focus the excitation light onto the device. After the excitation, the 
615nm AlphaLISA emission signal, which passed through the dichroic 
mirror and the 660 nm shortpass fi lter (ET660SP, Chroma, Bellows 
Falls, VT), was then detected by an electron multiplying charge-coupled 
device (EMCCD) camera (Photometrics, Tucson, AZ). The microscopic 
analysis software (NIS-Element BR, Nikon) was used to synchronize the 
timing of shutter in front of laser and the opening time of the EMCCD. 
The software simultaneously counted the AlphaLISA emission signal 
intensity from the EMCCD during the measurement. 
 Calibration of TNF- α Standard Curve: To generate the TNF- α 
standard curve, known amounts of TNF- α were spiked in RPMI media 
(0 − 5,000 pg mL  − 1 ). Then, 10  μ g mL  − 1 AlphaLISA acceptor beads, 
10 nM biotinylated TNF- α antibody and 400  μ g mL  − 1 streptavidin-coated 
donor beads were added to the RPMI media. The AlphaLISA signal was 
measured using our custom optical setup and was plotted as a function 
of TNF- α concentration to generate the TNF- α standard curve. 
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 Supporting Information is available from the Wiley Online Library or 
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